Literature DB >> 15317946

Contrast-enhanced voiding US for grading of reflux in adult patients prior to antireflux ureteral implantation.

Anna Lia Valentini1, Anna Maria De Gaetano, Laura Maria Minordi, Giuseppe Nanni, Francesco Citterio, Angelo Maria Viggiano, Valeria Tancioni, Carmelo Destito.   

Abstract

PURPOSE: To prospectively assess contrast material-enhanced voiding ultrasonography (US) for grading of vesicoureteral reflux (VUR) and to compare results with those of voiding cystourethrography (VCUG) in adult patients undergoing antireflux ureteral implantation.
MATERIALS AND METHODS: Thirty-seven consecutive adult patients who had undergone renal transplantation with Politano-Leadbetter (18 patients) or Lich-Gregoire (19 patients) technique were included on the basis of previous urinary tract infections (UTIs) and time elapsed after renal transplantation. Exclusion criterion was current UTI. US was performed by one of two sonologists with injection of saline and microbubble suspension and was recorded on videotape. Sonologists assigned VUR diagnosis in consensus after videotape review. VCUG was performed by one of two radiologists immediately after US. Radiologists were blinded to US findings and assigned VCUG diagnoses in consensus. Contingency table was used to compare US and VCUG. Agreement between US and VCUG was determined with kappa statistics.
RESULTS: With VCUG, VUR was diagnosed in 15 patients and not diagnosed in 22 patients. US and VCUG results were in agreement in 14 patients with VUR and 21 patients without VUR. US sensitivity and specificity for detection of VUR were 93% (14 true-positive results in 15 abnormal cases) and 95% (21 true-negative results in 22 normal cases), respectively. Agreement between US and VCUG was 95% (kappa = 0.89, P <.001). In 11 of 14 patients, VUR grades were in agreement for US and VCUG. In three of 14 patients, US indicated a higher grade than did VCUG. VUR was diagnosed in seven of 18 Politano-Leadbetter cases and eight of 19 Lich-Gregoire cases.
CONCLUSION: A high rate of agreement was seen between voiding US and VCUG. Copyright RSNA, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15317946     DOI: 10.1148/radiol.2331031803

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  7 in total

Review 1.  [Ultrasound contrast agents: substance classes, pharmacokinetics, clinical applications, safety aspects].

Authors:  C Krestan
Journal:  Radiologe       Date:  2005-06       Impact factor: 0.635

Review 2.  Contrast-enhanced ultrasonography (voiding urosonography) of vesicoureteral reflux: state of the art.

Authors:  G Zimbaro; G Ascenti; C Visalli; A Bottari; F Zimbaro; N Martino; S Mazziotti
Journal:  Radiol Med       Date:  2007-12-13       Impact factor: 3.469

3.  Vesicoureteral reflux in a nonfunctioning kidney detected by 99mTc-DTPA study.

Authors:  Ebru Orsal; Bedri Seven; Irmak Durur Subasi; Arif Kursad Ayan; Zeynep Akkan
Journal:  Jpn J Radiol       Date:  2013-11-01       Impact factor: 2.374

4.  Feasibility of superb microvascular imaging to detect high-grade vesicoureteral reflux in children with urinary tract infection.

Authors:  Hee Kyung Kim; Sara O'Hara; Bo-Kyung Je; Steven J Kraus; Paul Horn
Journal:  Eur Radiol       Date:  2017-07-28       Impact factor: 5.315

5.  Assessing vesicoureteral reflux in live inbred mice via ultrasound with a microbubble contrast agent.

Authors:  Jose Paredes; Sunder Sims-Lucas; Hang Wang; Weining Lu; Brian Coley; George K Gittes; Carlton M Bates
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-16

Review 6.  Voiding urosonography with US contrast agents for the diagnosis of vesicoureteric reflux in children. II. Comparison with radiological examinations.

Authors:  Kassa Darge
Journal:  Pediatr Radiol       Date:  2007-07-18

7.  Echocontrast cystosonography versus micturating cystourethrography in the detection of vesicoureteric reflux.

Authors:  Mz Faizah; Y Kanaheswari; Cr Thambidorai; Ma Zulfiqar
Journal:  Biomed Imaging Interv J       Date:  2011-01-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.